Annual report pursuant to Section 13 and 15(d)

SIGNIFICANT CONCENTRATIONS (Details)

v3.7.0.1
SIGNIFICANT CONCENTRATIONS (Details) - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
SIGNIFICANT CONCENTRATIONS    
Accounts receivable $ 0 $ 203,000
Sales | Customer concentration risk | Bristol-Myers Squibb Company    
SIGNIFICANT CONCENTRATIONS    
Concentration risk as a percentage of revenue 82.00% 60.00%
Sales | Customer concentration risk | Aclaris    
SIGNIFICANT CONCENTRATIONS    
Concentration risk as a percentage of revenue   28.00%
Sales | Customer concentration risk | Ber Gen Bio A S    
SIGNIFICANT CONCENTRATIONS    
Concentration risk as a percentage of revenue 18.00%  
Sales | Customer concentration risk | Third Party    
SIGNIFICANT CONCENTRATIONS    
Concentration risk as a percentage of revenue   12.00%
Accounts receivable | Credit concentration risk | Bristol-Myers Squibb Company    
SIGNIFICANT CONCENTRATIONS    
Accounts receivable   $ 203,000